Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LX102-C01
- Development stage
- Unknown
- Lead developer
- LEADS BioLabs
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Ophthalmic, Intravitreal
01
Overview
LX102-C01 is a recombinant human vascular endothelial growth factor (VEGF) receptor-antibody fusion protein developed by Nanjing Leads Biolabs. Functioning as a "VEGF trap," it is designed to bind and neutralize multiple pro-angiogenic factors, including Vascular Endothelial Growth Factor A (VEGF-A), Vascular Endothelial Growth Factor B (VEGF-B), and Placental Growth Factor (PlGF). These factors play a critical role in the pathological angiogenesis and vascular permeability that drive retinal diseases. LX102-C01 is specifically formulated for intravitreal administration and is being investigated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), with the goal of reducing retinal fluid and preventing vision loss in affected patients.
- Other names
- aflibercept biosimilar
02
Targets
VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on LX102-C01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LX102-C01.